191 related articles for article (PubMed ID: 31406003)
1. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.
Kuo J; Bobardt M; Chatterji U; Mayo PR; Trepanier DJ; Foster RT; Gallay P; Ure DR
J Pharmacol Exp Ther; 2019 Nov; 371(2):231-241. PubMed ID: 31406003
[TBL] [Abstract][Full Text] [Related]
2. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH).
Ure DR; Trepanier DJ; Mayo PR; Foster RT
Expert Opin Investig Drugs; 2020 Feb; 29(2):163-178. PubMed ID: 31868526
[No Abstract] [Full Text] [Related]
3. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
Gallay P; Ure D; Bobardt M; Chatterji U; Ou J; Trepanier D; Foster R
PLoS One; 2019; 14(6):e0217433. PubMed ID: 31181107
[TBL] [Abstract][Full Text] [Related]
4. Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
Stauffer WT; Bobardt M; Ure DR; Foster RT; Gallay P
PLoS One; 2024; 19(4):e0301711. PubMed ID: 38573968
[TBL] [Abstract][Full Text] [Related]
5. Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model.
Stauffer WT; Goodman AZ; Bobardt M; Ure DR; Foster RT; Gallay P
PLoS One; 2024; 19(3):e0298211. PubMed ID: 38427624
[TBL] [Abstract][Full Text] [Related]
6. Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
Bobardt M; Hansson MJ; Mayo P; Ure D; Foster R; Gallay P
PLoS One; 2020; 15(8):e0237236. PubMed ID: 32764799
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.
Simón Serrano S; Grönberg A; Longato L; Rombouts K; Kuo J; Gregory M; Moss S; Elmér E; Mazza G; Gallay P; Pinzani M; Hansson MJ; Massoumi R
Cells; 2019 Nov; 8(11):. PubMed ID: 31717385
[TBL] [Abstract][Full Text] [Related]
8. Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System.
Trepanier DJ; Ure DR; Foster RT
J Pharm Pharm Sci; 2018; 21(1s):335s-348s. PubMed ID: 30472978
[TBL] [Abstract][Full Text] [Related]
9. Cyclophilin inhibition as potential therapy for liver diseases.
Naoumov NV
J Hepatol; 2014 Nov; 61(5):1166-74. PubMed ID: 25048953
[TBL] [Abstract][Full Text] [Related]
10. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
11. Semisynthesis of CRV431.
Li FX; Zhang QZ; Li SJ; Lin G; Huo XY; Lan Y; Yang Z
Org Lett; 2021 May; 23(9):3421-3425. PubMed ID: 33844557
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B.
Trepanier DJ; Ure DR; Foster RT
Pharmaceutics; 2017 Nov; 9(4):. PubMed ID: 29120380
[TBL] [Abstract][Full Text] [Related]
13. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Fu J; Tjandra M; Becker C; Bednarczyk D; Capparelli M; Elling R; Hanna I; Fujimoto R; Furegati M; Karur S; Kasprzyk T; Knapp M; Leung K; Li X; Lu P; Mergo W; Miault C; Ng S; Parker D; Peng Y; Roggo S; Rivkin A; Simmons RL; Wang M; Wiedmann B; Weiss AH; Xiao L; Xie L; Xu W; Yifru A; Yang S; Zhou B; Sweeney ZK
J Med Chem; 2014 Oct; 57(20):8503-16. PubMed ID: 25310383
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
15. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
16. Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse.
Seniutkin O; Furuya S; Luo YS; Cichocki JA; Fukushima H; Kato Y; Sugimoto H; Matsumoto T; Uehara T; Rusyn I
Toxicol Appl Pharmacol; 2018 Jan; 339():1-9. PubMed ID: 29197520
[TBL] [Abstract][Full Text] [Related]
17. A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation.
Balsley MA; Malesevic M; Stemmy EJ; Gigley J; Jurjus RA; Herzog D; Bukrinsky MI; Fischer G; Constant SL
J Immunol; 2010 Dec; 185(12):7663-70. PubMed ID: 21057089
[TBL] [Abstract][Full Text] [Related]
18. From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
Sweeney ZK; Fu J; Wiedmann B
J Med Chem; 2014 Sep; 57(17):7145-59. PubMed ID: 24831536
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive activity of [MeBm2t]1-, D-diaminobutyryl-8-, and D-diaminopropyl-8-cyclosporin analogues correlates with inhibition of calcineurin phosphatase activity.
Nelson PA; Akselband Y; Kawamura A; Su M; Tung RD; Rich DH; Kishore V; Rosborough SL; DeCenzo MT; Livingston DJ
J Immunol; 1993 Mar; 150(6):2139-47. PubMed ID: 7680683
[TBL] [Abstract][Full Text] [Related]
20. Cyclophilin inhibitors.
Gallay PA
Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
